Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial

Annals of Internal Medicine

Volumn 163, Issue 1, 2015, Pages 1-13

  Zeuzem, Stefan ^a   Ghalib, Reem ^b   Reddy, K Rajender ^c   Pockros, Paul J ^d   Ari, Ziv Ben ^e   Zhao, Yue ^f   Brown, Deborah D ^f   Wan, Shuyan ^f   DiNubile, Mark J ^f   Nguyen, Bach Yen ^f   Robertson, Michael N ^f   Wahl, Janice ^f   Barr, Eliav ^f   Butterton, Joan R ^f  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Texas Clinical Research Institute   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^e SHEBA MEDICAL CENTER   (Israel)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ELBASVIR PLUS GRAZOPREVIR; PLACEBO; VIRUS RNA; 2-(PYRROLIDIN-2-YL)-5-(2-(4-(5-(PYRROLIDIN-2-YL)-1H-IMIDAZOL-2-YL)PHENYL)BENZOFURAN-5-YL)-1H-IMIDAZOLE; ANTIVIRUS AGENT; BENZOFURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; MK-5172; QUINOXALINE DERIVATIVE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; AUSTRALIA; CAUSE OF DEATH; CHRONIC HEPATITIS C; COMPARATIVE STUDY; CONTROLLED STUDY; CZECH REPUBLIC; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HEADACHE; HEART PALPITATION; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 6; HIATUS HERNIA; HUMAN; HYPERTRANSAMINASEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SWEDEN; TAIWAN; THROMBOCYTE COUNT; TREATMENT OUTCOME; UNITED STATES; VIREMIA; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DRUG ADMINISTRATION; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; BENZOFURANS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; GENOTYPE; HEADACHE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NAUSEA; QUINOXALINES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84937064772     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0785     Document Type: Article

References (32)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-62. [PMID: 23817321] doi:10.1038/nrgastro.2013.107
2. Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900. [PMID: 21427396] doi:10.1093/cid/cir076
3. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631-40. [PMID: 25117132] doi: 10.1001/jama.2014.7085
4. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012;56:4161-7. [PMID: 22615282] doi:10.1128/AAC.00324-12
5. Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59: 1657-65. [PMID: 25266289] doi:10.1093/cid/ciu696
6. Yeh WW, Lipardi C, Jumes P, De Lepeleire I, van den Bulk N, Caro L. MK-8742, a HCV NS5A inhibitor with a broad spectrum of HCV genotype activity, demonstrates potent antiviral activity in genotype-1 and-3 HCV-infected patients [Abstract]. In: Proceedings of the 64th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC, 1-5 November 2013. Abstract 479.
7. Lahser F, Liu R, Bystol K, Xia E, Asante-Appiah E, Howe AY. A combination containing MK-5172 (HCV N53 protease inhibitor) and MK-8742 (HCV NS5A inhibitor) demonstrates high barrier to resistance in HCV replicons [Abstract]. In: Proceedings of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 9-13 November 2012. Abstract 87.
8. Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Gastroenterology. 2014;147:366-76.e6. [PMID: 24727022] doi:10.1053/j.gastro.2014.04.006
9. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, openlabel phase 2 trial. Lancet. 2015;385:1075-86. [PMID: 25467591] doi: 10.1016/S0140-6736(14)61795-5
10. Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1087-97. [PMID: 25467560] doi:10.1016/S0140-6736(14)61793-1
11. Boursier J, de Ledinghen V, Zarski JP, Fouchard-Hubert I, Gallois Y, Oberti F, et al; multicentric groups from SNIFF 32, VINDIAG 7, and ANRS/HC/EP23 FIBROSTAR studies. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55:58-67. [PMID: 21898504] doi:10.1002/hep.24654
12. Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyö EM, et al. Analysis of heterogeneous viral populations by direct DNA sequencing. Biotechniques. 1993;15:120-7. [PMID: 8363827]
13. Koletzki D, Pattery T, Fevery B, Vanhooren L, Stuyver LJ. Amplification and sequencing of the hepatitis C virus NS3/4A protease and the NS5B polymerase regions for genotypic resistance detection of clinical isolates of subtypes 1a and 1b. Methods Mol Biol. 2013; 1030:137-49. [PMID: 23821266] doi:10.1007/978-1-62703-484-5-12
14. Phenotype Working Group, Drug Development Advisory Group 2012. Clinically relevant HCV drug resistance mutations figure and tables (updated). Ann Forum Collab HIV Res. 2012;14:1-10. Accessed at: www.idsociety.org/uploadedFiles/IDSA/Hepatitis-C/For-IDSA-Members/ForumforCollaborativeHIV-ClinicallyRelevantHCVDrug.pdf on 29 January 2015.
15. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebocontrolled trial. Lancet. 2014;384:403-13. [PMID: 24907225] doi:10.1016/S0140-6736(14)60494-3
16. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2014;384:414-26. [PMID: 24907224] doi:10.1016/S0140-6736(14)60538-9
17. Chen J, Florian J, Carter W, Fleischer RD, Hammerstrom TS, Jadhav PR, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144:1450-1455.e2.[PMID:23470616]doi:10.1053/j.gastro.2013.02.039
18. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404-413.
19. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-98. [PMID: 24725239] doi:10.1056/NEJMoa1402454
20. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370: 1879-88. [PMID: 24720702] doi:10.1056/NEJMoa1402355
21. Brown A, Hezode C, Zuckerman E, Foster G, Zekry A, Roberts S, et al. C-SCAPE: Efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5 or 6 infection [Abstract]. In: Proceedings of the 50th International Liver Congress, Vienna, Austria, 22-26 April 2015. Abstract P0771.
22. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015 Mar 30. doi: 10.1016/S0140-6736(15)60159-3. [Epub ahead of print]
23. Naggie S, Cooper C, Saag MS, Yang J, Stamm L, Pang P, et al. Ledipasvir/sofosbuvir for 12 weeks in patients coinfected with HCV and HIV-1. In: Proceedings of the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 23-26 February 2015.
24. Wyles D, Ruane P, Sulkowksi M, Dieterich D, Luetkemeyer A, Morgan T, et al. Daclatasvir in combination with sofosbuvir for HIV/HCV coinfection: ALLY-2 study [Abstract]. In: Proceedings of the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 23-26 February 2015. Abstract 151LB.
25. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-87. [PMID: 23607594] doi:10.1056/NEJMoa1214853
26. Gane EJ, Hyland RH, An D, Svarovskaia E, Pang P, Symonds W, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection [Abstract]. In: Proceedings of the 65th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Massachusetts, 7-11 November 2014. Abstract LB-11.
27. Janssen Products. Olysio (simeprevir) capsules, for oral use. Titusville, NJ: Janssen Therapeutics; revised November 2014.
28. AbbVie. Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. North Chicago, IL: AbbVie; February 2015.
29. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al; PEARL-III Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92. [PMID: 24795200] doi:10.1056/NEJMoa1402338
30. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603. [PMID: 24720703] doi:10.1056/NEJMoa1315722
31. Gilead Sciences. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use. Foster City, CA: Gilead Sciences; October 2014. 32
32. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir/elbasvir plus ribavirin for chronic HCV genotype-1 Infection after failure of combination therapy containing a directacting antiviral agent. J Hepatol. [Forthcoming]